Case Studies
Vaccine Equity
Vaccine Equity became a key issue during the Covid 19 pandemic. It affected millions of people who needed access to the same life-saving drugs as the developed world. Many pharmaceuticals organisations and governments found themselves in the crosshairs of public opprobrium.
Rebbelith was tasked with assisting an international pharmaceuticals organisation to navigate this debate. This was achieved by helping them understand the complex stakeholder influence networks and multiple public discussions over a year.
Key questions
-
Which individuals and organisations influence key stakeholders in the global debate on Vaccine Equity?
-
Which media and journalists drive each specific subtopic in the Vaccine Equity debate?
-
What is the structure of the global media debate on Vaccine Equity and how is it changing?
Identified 793 individuals and organisations influencing the stakeholder group comprising:
-
140 individuals at NGOs
-
222 NGOs
-
118 ex or serving Government Individuals
-
83 valued media publications and over 40 specific journalists
-
Isolated 55 individuals and organisations that reached at least 20% of the stakeholder group
7 dominant media discussions targeted:
-
IP of large pharmaceutical companies
-
International collaboration (NGO, Gov, IGO & Corporate) & 'pandemic preparedness'
-
Production & logistics (including EU dose wastage, data transfer & African self-sufficiency)
-
EU- African relations and foreign power influence (including the central role of China dose donations and investment)
-
Covax success & dose donations by individual nation states
-
Vaccine hoarding
-
New Covid-19 variants, particularly high-income nation demand pressure created by Omicron booster campaigns